One drug to treat Alzheimer’s, MS and brain injury?

Alzheimer’s, Parkinson’s disease, multiple sclerosis and traumatic brain injury are four neurodegenerative disorders with very different – and very devastating – effects on the brain and daily life.

While there are multiple treatments and therapies aimed at fighting each of these conditions separately, a team of researchers from Northwestern University Feinberg School of Medicine have developed a new “one-size-fits-all” therapy drug that could potentially treat all of them.

The drug’s trick lies in reducing a particular type of inflammation in the brain known as neuroinflammation.  This brain response has become increasingly considered a common denominator for many neurological disorders, as well as playing a major role in brain injuries.  To decrease inflammation, the drug developed at Northwestern binds to and decreases a molecule known as cytokine, which is released in large quantities during the neuroinflammatory response.

“We faced two main challenges,” Dr. Martin Watterson, a professor of molecular pharmacology and biological chemistry at the Feinberg School, as well as the lead developer of the drug, told  “Come up with something to tone down the inflammatory response and do it with some selectivity [so that the immune response would not be toned down as well].  “We wanted to have a small molecule taken by mouth once or twice a day that would be relatively safe and get into the brain.”

Click here to read more.